Literature DB >> 17617115

Dietary iron overload in the African and hepatocellular carcinoma.

Michael C Kew1, George A Asare.   

Abstract

Dietary iron overload occurs commonly in parts of sub-Saharan Africa. It results from the consumption of large volumes of traditional beer that is home-brewed in iron pots or drums and consequently has a high iron content. The liver becomes iron overloaded and may develop portal fibrosis or, less often, cirrhosis. A genetic predisposition to the condition has been suggested, but no putative gene has yet been identified. Although originally believed not to cause hepatocellular carcinoma, recent case-control studies have shown African Blacks with dietary iron overload to be at increased risk for the tumour and a causal association has been confirmed in an animal model. The mechanisms of iron-induced malignant transformation are yet to be fully characterised, but the close association between cirrhosis and hepatocellular carcinoma in patients with hereditary haemochromatosis and the lesser association in those with dietary iron overload, suggests that chronic necroinflammatory hepatic disease contributes to the malignant transformation. Increased hepatic iron may, however, also be directly carcinogenic. Probable mechanisms include the generation of reactive oxygen intermediates and the resultant chronic oxidative stress that damages hepatocytes and proteins, causes lipid peroxidation, and induces strand breaks, DNA unwinding, and mutations in tumour-suppressor genes and critical DNA repair genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617115     DOI: 10.1111/j.1478-3231.2007.01515.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  13 in total

Review 1.  The role of cirrhosis in the etiology of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastrointest Cancer       Date:  2014-03

2.  Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis.

Authors:  Michael C Kew
Journal:  World J Hepatol       Date:  2010-02-27

Review 3.  Alcoholic and non-alcoholic steatohepatitis.

Authors:  Manuela G Neuman; Samuel W French; Barbara A French; Helmut K Seitz; Lawrence B Cohen; Sebastian Mueller; Natalia A Osna; Kusum K Kharbanda; Devanshi Seth; Abraham Bautista; Kyle J Thompson; Iain H McKillop; Irina A Kirpich; Craig J McClain; Ramon Bataller; Radu M Nanau; Mihai Voiculescu; Mihai Opris; Hong Shen; Brittany Tillman; Jun Li; Hui Liu; Paul G Thomes; Murali Ganesan; Steve Malnick
Journal:  Exp Mol Pathol       Date:  2014-09-11       Impact factor: 3.362

4.  Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma.

Authors:  Vishnudutt Purohit; Rao Rapaka; Oh Sang Kwon; B J Song
Journal:  Life Sci       Date:  2012-10-30       Impact factor: 5.037

5.  Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.

Authors:  Sandhya R Panch; Yu Ying Yau; Kamille West; Karen Diggs; Tamsen Sweigart; Susan F Leitman
Journal:  Transfusion       Date:  2014-09-11       Impact factor: 3.157

Review 6.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

7.  The relationship between indices of iron status and selected anthropometric cardiovascular disease risk markers in an African population: the THUSA study.

Authors:  O R Aderibigbe; P T Pisa; R L Mamabolo; H S Kruger; H H Vorster
Journal:  Cardiovasc J Afr       Date:  2011-05-10       Impact factor: 1.167

Review 8.  Diagnosis and Management of Genetic Iron Overload Disorders.

Authors:  William C Palmer; Prakash Vishnu; William Sanchez; Bashar Aqel; Doug Riegert-Johnson; Leigh Ann Kenda Seaman; Andrew W Bowman; Candido E Rivera
Journal:  J Gen Intern Med       Date:  2018-09-17       Impact factor: 6.473

9.  Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.

Authors:  Naoki Yamamoto; Takahiro Yamasaki; Taro Takami; Koichi Uchida; Koichi Fujisawa; Toshihiko Matsumoto; Issei Saeki; Shuji Terai; Isao Sakaida
Journal:  J Clin Biochem Nutr       Date:  2016-03-15       Impact factor: 3.114

Review 10.  Hepatocellular carcinoma: epidemiology and risk factors.

Authors:  Michael C Kew
Journal:  J Hepatocell Carcinoma       Date:  2014-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.